Press release | 29th January 2007
Principal Biopharmaceutical Company Introduces ActivityBase XE to Improve Screening Efficiency
Guildford, United Kingdom, January 29, 2007 – IDBS today announces that long time ActivityBase user, Organon (Oss, The Netherlands and Newhouse, UK), has introduced the XE module into its Molecular Pharmacology departments in Oss and Newhouse. This follows a comprehensive pilot of XE and extensive collaboration with IDBS.
Organon incorporated the ActivityBase test management system in 2002, to improve efficiency in compound screening. Following the release of XE in September 2005, Organon sought to evaluate IDBS’ screening-specific module.
Dr Steven van Helden, Section Head for Screening and Technology at Organon, commented: “We have been very satisfied with our ActivityBase installation but constantly look for ways to improve efficiency within our screening process. As we recently introduced a new laboratory automation platform for in-vitro testing it was clear that there was also a desire to improve on our data processing. The attraction of the XE module was the ability to perform verification, analysis and visualisation within one environment. This greatly improves our workflow for High Throughput Screening, Hit Optimisation and Lead Optimisation.” Dr van Helden continued: “The designer element of XE, being linked to the context of the experiments, reduces the time and effort associated with template maintenance.
This means we can spend more time analysing data, and less time developing analysis templates.”
Neil Kipling, CEO and founder of IDBS, added: “We have many thousands of ActivityBase users – most of whom are engaged in biological screening. The addition of XE to ActivityBase makes it even more applicable and useful to an organisation’s HTS program. Providing context around screening results promotes better understanding, which in turn supports better decision-making.”
Organon – with shared head offices in Roseland, NJ, USA and Oss, The Netherlands – creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading biopharmaceutical companies in each of its core therapeutic fields: fertility, gynecology, anesthesia and neuroscience. Research areas also include immunology and oncology.
Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.